Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment. Click here to read an ...

Amgen Inc. closed 14.87% below its 52-week high of $346.85, which the company reached on July 25th.

Amgen Inc. closed 13.40% below its 52-week high of $346.85, which the company achieved on July 25th.

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Amgen (AMGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Amgen has transitioned into a mature, cash-generating pharma-biotech hybrid. Click here to find out why AMGN stock is a Buy.

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an eight-week period.

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like vomiting, according to mid-stage trial results presented at a medical meeting ...

Amgen said on Monday its experimental therapy helped patients with advanced gastric cancer live longer when combined with ...

The idea for Amgen’s first foray into documentary film started with two numbers, according to Nerissa Gomes, general manager ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Amgen (AMGN) one of those stocks right now? A quick glance at ...

In a report released on July 8, Courtney Breen from Bernstein maintained a Buy rating on Amgen, with a price target of $350.00. The company’s shares closed yesterday at $295.27. Breen covers the ...